PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32174780-6 2020 S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125. pyrazolanthrone 191-199 mitogen-activated protein kinase 14 Homo sapiens 63-66 34199278-5 2021 Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively. pyrazolanthrone 44-52 mitogen-activated protein kinase 14 Homo sapiens 119-122 34411914-10 2021 Moreover, TG and 22-HTG induced DNA double-strand break and phosphorylation of JNK2 (T183/Y185) and p38alpha (T180/Y182), and co-incubation with SP 600125 (JNK/SAPK inhibitor) and PD 169316 (p38 MAPK inhibitor) partially prevented apoptosis induced by TG and 22-HTG. pyrazolanthrone 145-154 mitogen-activated protein kinase 14 Homo sapiens 100-108 30368882-7 2019 Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression. pyrazolanthrone 42-50 mitogen-activated protein kinase 14 Homo sapiens 292-295 31505769-6 2019 Moreover, p38-MAPK/JNK inhibitors SB203580 and SP600125 promoted ex vivo expansion of CD34+ cells. pyrazolanthrone 47-55 mitogen-activated protein kinase 14 Homo sapiens 10-13 30439377-9 2018 SB203580 and SP600125 (p38 and JNK pathway inhibitors, respectively) attenuated GABA plus piperine-induced EPO and EPO-R expression. pyrazolanthrone 13-21 mitogen-activated protein kinase 14 Homo sapiens 23-26 29749481-9 2018 In addition, the inhibition of c-Jun N-terminal kinase (JNK)/p38 activity with SP600125/SB203580 decreased the expression of Gadd45a, whereas the inactivation of extracellular signal-regulated kinase with SCH772984 had no effect on the expression of Gadd45a. pyrazolanthrone 79-87 mitogen-activated protein kinase 14 Homo sapiens 61-64 30073566-6 2018 Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2. pyrazolanthrone 63-71 mitogen-activated protein kinase 14 Homo sapiens 178-181 29264665-4 2018 Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced lipopolysaccharide-induced production of inflammatory mediators and activation of the JNK and p38-MAPK in keratinocytes. pyrazolanthrone 25-33 mitogen-activated protein kinase 14 Homo sapiens 161-164 28389245-7 2017 The activation of JNK and p38 was also critical for thymol-induced apoptosis since it was abrogated by the treatment of JNK inhibitor (SP600125), and p38 inhibitor (SB203580) but not ERK inhibitor (SCH772984). pyrazolanthrone 135-143 mitogen-activated protein kinase 14 Homo sapiens 26-29 28432555-5 2017 Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes. pyrazolanthrone 25-33 mitogen-activated protein kinase 14 Homo sapiens 186-189 30003858-12 2018 The combinational treatment with P38-specific inhibitor SB202190 and JUN-specific inhibitor SP600125 significantly suppressed cell growth and migration, which was further attributed to the induction of autophagy flux and inhibition of EMT processing. pyrazolanthrone 92-100 mitogen-activated protein kinase 14 Homo sapiens 33-36 28962172-15 2017 Phospho-ERK, p38 and JNK were markedly increased by psoralen compared with the control group (P<0.05), and the specific inhibitors of ERK (SCH772984), p38 (SB203580) and JNK (SP600125) reversed the stimulatory effects of psoralen on signal marker phosphorylation (P<0.05). pyrazolanthrone 178-186 mitogen-activated protein kinase 14 Homo sapiens 154-157 28455228-5 2017 However, SP600125 could not only abrogated the JNK activation caused by brusatol, but also reverse the p38 activation and the decrease of Bcl-2 as SB203580 did. pyrazolanthrone 9-17 mitogen-activated protein kinase 14 Homo sapiens 103-106 27106512-9 2016 The amentoflavone-induced increases of ALP and mineralization were significantly diminished when the JNK and p38 MAPK pathways were blocked by selected inhibitors (SP600125, SB203580) in hMSCs. pyrazolanthrone 164-172 mitogen-activated protein kinase 14 Homo sapiens 109-112 26497035-7 2016 Moreover, thrombin-stimulated PKCalpha/betaII, PKCdelta, p38 MAPK, JNK1/2, or p65 phosphorylation was abrogated by their respective inhibitor of PPACK, GPA2A, D609, ET-18-OCH3, Go6983, Rottlerin, SB202190, SP600125, Bay11-7082, or Helenalin. pyrazolanthrone 206-214 mitogen-activated protein kinase 14 Homo sapiens 57-60 27570977-5 2016 Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential. pyrazolanthrone 129-137 mitogen-activated protein kinase 14 Homo sapiens 70-73 27570977-5 2016 Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential. pyrazolanthrone 129-137 mitogen-activated protein kinase 14 Homo sapiens 190-193 27597132-10 2016 We also observed that pretreatment with the JNK and p38 inhibitors (SP600125 and SB203580) decreased GEN-induced cell death. pyrazolanthrone 68-76 mitogen-activated protein kinase 14 Homo sapiens 52-55 27490539-6 2016 Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125. pyrazolanthrone 285-293 mitogen-activated protein kinase 14 Homo sapiens 173-209 27096061-5 2016 The inhibitors SB203580, PD98059 and SP600125 were used for suppressing the expression of p38 mitogen-activated protein kinase (MAPK), p44/42 MAPK and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK). pyrazolanthrone 37-45 mitogen-activated protein kinase 14 Homo sapiens 90-126 25611974-8 2015 JNK and p38 inhibitors (SP600125 and SB203580, respectively) reversed TQ autophagic cell death. pyrazolanthrone 24-32 mitogen-activated protein kinase 14 Homo sapiens 8-11 25619392-8 2015 Pretreatment with the p38 inhibitor SB202190 or the JNK inhibitor SP600125 dose-dependently reduced resveratrol-induced phosphorylation of H2AX, which were also observed when the cells were transfected with p38- or JNK-specific siRNAs. pyrazolanthrone 66-74 mitogen-activated protein kinase 14 Homo sapiens 207-210 25573072-10 2015 Finally, pharmacological inhibitors OA, SB203580, SP600125 and PD98059 confirm the role of PP2A and its substrates ERK, p38 MAPK and Akt in mediating TP/HCPT-induced apoptosis. pyrazolanthrone 50-58 mitogen-activated protein kinase 14 Homo sapiens 120-123 26238193-11 2015 When the phosphorylation of p38 and JNK were inhibited by SB203580 (p38 inhibitor) or SP600125 (JNK inhibitor), respectively, the NOV-induced proliferation inhibition and cell apoptosis were reversed. pyrazolanthrone 86-94 mitogen-activated protein kinase 14 Homo sapiens 28-31 25862966-8 2015 Co-treatment with MAPKs inhibitors U0126, SB202190 and SP600125 indicated JNK and p38 pathways were involved in the course. pyrazolanthrone 55-63 mitogen-activated protein kinase 14 Homo sapiens 82-85 25446857-7 2015 Immunoblots showed that the reduction of the Bcl-2/Bax ratio, the induction of caspase 3 cleavage, and the induction of poly(ADP-ribose) polymerase (PARP) cleavage by 6-OHDA was reversed in the presence of SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) in SH-SY5Y cells. pyrazolanthrone 236-244 mitogen-activated protein kinase 14 Homo sapiens 218-221 24963048-10 2014 Moreover, JNK inhibition by SP600125 or MKK7 siRNA knockdown antagonized the effects of p38 inhibition by SB202190. pyrazolanthrone 28-36 mitogen-activated protein kinase 14 Homo sapiens 88-91 26645893-7 2015 Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK. pyrazolanthrone 66-74 mitogen-activated protein kinase 14 Homo sapiens 29-32 26645893-7 2015 Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK. pyrazolanthrone 66-74 mitogen-activated protein kinase 14 Homo sapiens 153-156 26645893-7 2015 Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK. pyrazolanthrone 66-74 mitogen-activated protein kinase 14 Homo sapiens 153-156 26783410-9 2015 Moreover, bufalin increased the phosphorylation of JNK and p38-MAPK in CAPAN-2 and CAL-27 cells, and blocking the JNK/p38-MAPK pathway using the JNK inhibitor SP600125 or the p38-MAPK inhibitor SB203580 reversed bufalin-induced hTERT downregulation. pyrazolanthrone 159-167 mitogen-activated protein kinase 14 Homo sapiens 118-121 26783410-9 2015 Moreover, bufalin increased the phosphorylation of JNK and p38-MAPK in CAPAN-2 and CAL-27 cells, and blocking the JNK/p38-MAPK pathway using the JNK inhibitor SP600125 or the p38-MAPK inhibitor SB203580 reversed bufalin-induced hTERT downregulation. pyrazolanthrone 159-167 mitogen-activated protein kinase 14 Homo sapiens 118-121 24963048-11 2014 In vivo, SP600125 significantly decreased growth rates of xenografts with high p38 activity compared with those without p38 expression. pyrazolanthrone 9-17 mitogen-activated protein kinase 14 Homo sapiens 79-82 23172806-9 2014 Similarly, SP600125, an inhibitor of SAPK/JNK, moderately inhibited cytotoxicity and apoptosis induced by p-PD, thus implying that p38 MAPK and SAPK/JNK had a partial role in p-PD-induced apoptosis. pyrazolanthrone 11-19 mitogen-activated protein kinase 14 Homo sapiens 131-134 24706573-6 2014 Similarly, the inhibition of JNK signal pathway activation by pretreatment with SP600125 facilitated the protein phosphorylation of p38 MAPK caused by OA. pyrazolanthrone 80-88 mitogen-activated protein kinase 14 Homo sapiens 132-135 21946058-11 2012 The inhibitors of p38(MAPK) (sb202190) and JNK (sp600125) enhanced the inhibition induced by As2O3, which was counteracted by anisomycin, an activating agent of p38(MAPK) and JNK. pyrazolanthrone 48-56 mitogen-activated protein kinase 14 Homo sapiens 161-164 24731555-7 2014 In addition, we found that various inhibitors, such as the PLCgamma2 inhibitor U73122, the PKC inhibitor Ro318220, the phospoinositide 3-kinase inhibitor LY294002, the p38 mitogen-activated protein kinase inhibitor SB203580, the ERK inhibitor PD98059, and the JNK inhibitor SP600125, had no effects on collagen-induced JAK2 activity. pyrazolanthrone 274-282 mitogen-activated protein kinase 14 Homo sapiens 168-171 23067223-8 2013 The activation of p38 and JNK could be blocked by respective inhibitors (SB203580 for p38 and SP600125 for JNK) accompanied with the inhibition of apoptosis and changes of apoptosis associated proteins in CEM-C1 cells. pyrazolanthrone 94-102 mitogen-activated protein kinase 14 Homo sapiens 18-21 22142847-4 2012 In addition, the selective p38 inhibitor SB203580 suppressed PhSe-T/MeSe-T-induced apoptosis and activation of caspase-3, -9, -8, and -2, whereas the jun amino-terminal kinase (JNK) inhibitor SP600125 and the ERK inhibitor PD98059 had no effect. pyrazolanthrone 192-200 mitogen-activated protein kinase 14 Homo sapiens 27-30 23796709-9 2013 JNK and p38 specific inhibitors, SB203580 and SP600125 respectively, significantly blocked the cytotoxic effects of PL in LN229 and U87 cells. pyrazolanthrone 46-54 mitogen-activated protein kinase 14 Homo sapiens 8-11 23376055-8 2013 TGF-beta1-induced EMT occurred through phosphorylation of p38 MAPK and JNK and was inhibited by inhibitor SB-203580 and SP-600125 and gene silencing. pyrazolanthrone 120-129 mitogen-activated protein kinase 14 Homo sapiens 58-61 23211822-7 2013 U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively. pyrazolanthrone 21-29 mitogen-activated protein kinase 14 Homo sapiens 57-60 23047827-6 2012 Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation. pyrazolanthrone 90-98 mitogen-activated protein kinase 14 Homo sapiens 159-162 20607722-6 2010 MMP-2 promoter activity and cell invasion were inhibited by p38 mitogen-activated protein kinase (MAPK) siRNA, inhibitor 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole (SB203580), and AE, but not by JNK siRNA and inhibitor 1,9-pyrazoloanthrone. pyrazolanthrone 251-271 mitogen-activated protein kinase 14 Homo sapiens 60-96 19852986-6 2010 In addition, CRH treatment induced rapid phosphorylation of p38 MAPK and JNK1/2, and antalarmin, SB203580 and SP600125 inhibited CRH-induced phosphorylation of p38 MAPK and JNK1/2. pyrazolanthrone 110-118 mitogen-activated protein kinase 14 Homo sapiens 160-163 20380623-4 2010 To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively. pyrazolanthrone 133-141 mitogen-activated protein kinase 14 Homo sapiens 102-105 20177146-3 2010 Inhibition of p38 MAPK and JNK by their specific inhibitors (SB203580 and SP600125), or inhibition by a dominant negative mutant of p38 MAPK dramatically decreased SAA-induced CCL2 production. pyrazolanthrone 74-82 mitogen-activated protein kinase 14 Homo sapiens 14-17 20096139-7 2010 Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis. pyrazolanthrone 174-182 mitogen-activated protein kinase 14 Homo sapiens 49-52 20096139-7 2010 Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis. pyrazolanthrone 174-182 mitogen-activated protein kinase 14 Homo sapiens 93-96 19616567-9 2009 Pre-treatment with SP600125 (JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated NF-kappaB and IKK phosphorylation indicating that p38 and JNK MAPKs are mainly involved in arsenic-induced NF-kappaB activation. pyrazolanthrone 19-27 mitogen-activated protein kinase 14 Homo sapiens 139-142 19288033-7 2009 As expected, PD98059, an ERK inhibitor, SP600125, a JNK inhibitor and SB203580, a p38 MAPK inhibitor effectively inhibit UVB-induced phosphorylation of ERK, JNK and p38 MAPKs, respectively. pyrazolanthrone 40-48 mitogen-activated protein kinase 14 Homo sapiens 165-168 19558546-9 2009 The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38. pyrazolanthrone 77-85 mitogen-activated protein kinase 14 Homo sapiens 158-161 19558546-9 2009 The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38. pyrazolanthrone 77-85 mitogen-activated protein kinase 14 Homo sapiens 278-281 19201463-5 2009 TNF-mediated stimulation of CCL2 secretion was completely inhibited by incubating the trophoblast cells with the p38-MAPK inhibitor SB203580, whereas CCL5 secretion was inhibited by treating the trophoblast cells with inhibitors specific for JNK (SP600125) and ERK kinase (U0126). pyrazolanthrone 247-255 mitogen-activated protein kinase 14 Homo sapiens 113-116 19154444-7 2009 We found that mainly p38, p42 and p46 MAPKs were phosphorylated by SP and SB202190, PD98059 and SP600125, which are selective inhibitors of these kinases, blocked SP-induced COX-2 expression. pyrazolanthrone 96-104 mitogen-activated protein kinase 14 Homo sapiens 21-24 19471112-7 2009 However, treatment of cells with SB202190 or SP600125, inhibitors of p38 MAPK and JNK respectively, did not affect HUVEC migration. pyrazolanthrone 45-53 mitogen-activated protein kinase 14 Homo sapiens 69-72 18084318-8 2008 Pretreatment with SB202190 or SP600125, specific inhibitors of p38 and JNK MAPKs, respectively, reduced ICAM-1 and VCAM-1 expression in HT29 cells dose-dependently. pyrazolanthrone 30-38 mitogen-activated protein kinase 14 Homo sapiens 63-66 19505051-4 2009 The action of inhibitors of MAP-kinases JNK (SP600125) and p38 (ML3403) in vitro under condition of oxidative stress prevents increase in the quantity of annexin-positive mononuclear leucocytes that testifies to involving JNK and p38 MAP-kinases in apoptosis deregulation oxidative mechanisms. pyrazolanthrone 45-53 mitogen-activated protein kinase 14 Homo sapiens 230-233 18552392-11 2008 Pretreatment of cells with SB203580, an inhibitor for p38MAP kinase, reduced the H(2)O(2)- and TGF-beta2-stimulated Hsp27 expression, whereas pretreatment with PD98059 and U0126, specific inhibitors of ERK1/2, and SP600125, a specific c-Jun N-terminal kinase inhibitor, had no effects. pyrazolanthrone 214-222 mitogen-activated protein kinase 14 Homo sapiens 54-67 18058803-7 2008 SP600125, a specific inhibitor for JNK and SB203580, a p38 MAPK-specific inhibitor suppressed AMR-Me induced apoptosis indicating that activation of JNK and p38 MAPKs involved in the mitochondrial activation-mediated cell death pathway. pyrazolanthrone 0-8 mitogen-activated protein kinase 14 Homo sapiens 55-58 18058803-7 2008 SP600125, a specific inhibitor for JNK and SB203580, a p38 MAPK-specific inhibitor suppressed AMR-Me induced apoptosis indicating that activation of JNK and p38 MAPKs involved in the mitochondrial activation-mediated cell death pathway. pyrazolanthrone 0-8 mitogen-activated protein kinase 14 Homo sapiens 157-160 17311279-6 2007 IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively. pyrazolanthrone 124-132 mitogen-activated protein kinase 14 Homo sapiens 53-56 17067555-9 2007 COX-2 expression in response to IL-1beta was attenuated by pretreatment with SB203580, SP600125, and LY294002, but not with PD98059, suggesting the involvement of p38 MAPK, JNK, and PI3K in this response. pyrazolanthrone 87-95 mitogen-activated protein kinase 14 Homo sapiens 163-166 17305717-4 2007 Blockade of the p38 MAPK and JNK pathways with the respective upstream inhibitors (SB203580 and SP600125) abolished the TGF-beta1-mediated induction of NGF. pyrazolanthrone 96-104 mitogen-activated protein kinase 14 Homo sapiens 16-19 17143555-9 2007 SB203580 and SP600125 (p38 and JNK inhibitors) reduced diosgenin-induced DNA fragmentation whereas U0126 and LY294002 (MEK and PI3 kinase/Akt inhibitors) caused an amplification of proapoptotic effect of diosgenin. pyrazolanthrone 13-21 mitogen-activated protein kinase 14 Homo sapiens 23-26 15161854-9 2004 Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK. pyrazolanthrone 41-49 mitogen-activated protein kinase 14 Homo sapiens 208-211 16651444-8 2006 Using specific kinase inhibitors (SB203580 and SP600125), we showed the central role of p38 and c-Jun NH(2)-terminal kinase (JNK) pathways in 3,3"-diindolylmethane-induced p21 mRNA transcription. pyrazolanthrone 47-55 mitogen-activated protein kinase 14 Homo sapiens 88-91 15964311-10 2005 Both SP600125 and SB203580 significantly prevented the phosphorylation of JNK and p38 proteins, but not ERK. pyrazolanthrone 5-13 mitogen-activated protein kinase 14 Homo sapiens 82-85 16000878-4 2005 Among several signal pathway inhibitors tested, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, completely blocked the CD9-stimulated MMP-2 expression. pyrazolanthrone 61-69 mitogen-activated protein kinase 14 Homo sapiens 85-88 15161854-9 2004 Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK. pyrazolanthrone 41-49 mitogen-activated protein kinase 14 Homo sapiens 84-87 15971988-6 2005 The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity. pyrazolanthrone 18-26 mitogen-activated protein kinase 14 Homo sapiens 194-197 15489374-4 2005 Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively. pyrazolanthrone 137-146 mitogen-activated protein kinase 14 Homo sapiens 67-70 14741745-6 2004 Treatment with specific inhibitors of p38 MAP kinase (SB203580) and JNK (SP600125) activities markedly impaired the adaptation of Dunaliella to osmotic stress. pyrazolanthrone 73-81 mitogen-activated protein kinase 14 Homo sapiens 38-41 14551401-8 2003 U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively. pyrazolanthrone 21-29 mitogen-activated protein kinase 14 Homo sapiens 62-65 12527812-10 2003 Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis. pyrazolanthrone 63-94 mitogen-activated protein kinase 14 Homo sapiens 274-277 12527812-10 2003 Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis. pyrazolanthrone 96-104 mitogen-activated protein kinase 14 Homo sapiens 274-277